logo
Plus   Neg
Share
Email

Neurocrine Biosciences, Idorsia Amend Option Agreement To License ACT-709478

Neurocrine Biosciences, Inc. (NBIX) and Idorsia Ltd. have amended their 2019 agreement granting Neurocrine Biosciences an option to license ACT-709478, a potent brain penetrating T-type calcium channel blocker in development for epilepsy.

Upon Investigational New Drug application acceptance by the FDA, expected in mid-2020, Neurocrine Biosciences will have 30 days to exercise the option to license ACT-709478. If the option is exercised by Neurocrine Biosciences, Idorsia will receive an upfront payment of $45 million. Idorsia may also receive up to $365 million in additional development and regulatory milestone payments.

Also, Neurocrine Biosciences will provide an incremental $7 million in funding to Idorsia as part of the research collaboration.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Tesla said it will produce ventilators at its Gigafactory in Buffalo, New York to support the city's hospitals amid the coronavirus pandemic. New York is the worst affected state in the U.S. Last Saturday, Musk tweeted that he "had a long engineering discussion with Medtronic about state-of-the-art ventilators. Luxury fashion house Ralph Lauren will donate $10 million to help fight the coronavirus pandemic and manufacture face masks as well as medical gowns in the U.S. The company's charity arm, the Ralph Lauren Corporate Foundation, said in a statement that it is committing $10 million towards the global response to the COVID-19 pandemic. General Motors Co. is delaying work on new vehicle models and is cutting pay for its executives as part of efforts to conserve cash amid the coronavirus or Covid-19 pandemic. The automotive giant also extended the shutdown of North American plants indefinitely. Multiple reports cited an internal memo that salaried workforce will have 20 percent of pay deferred starting April 1.
Follow RTT
>